In a blind retrospective study carried out in accordance with guidelines for reporting of tumor marker studies (REMARK) [15] and standards for reporting diagnostic test accuracy (STARD) [16], we show that the presence of PS in blood accurately detects ovarian cancers and differentiates between patients with benign and malignant disease. These data suggest that the presence of PS in patient blood is diagnostic for cancer.